Table 1 Clinical characteristics of patients and controls
From: Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD
Control | Stable | Exacerbated | p-value | |
|---|---|---|---|---|
COPD | ||||
Number (male) | 15 (6) | 29 (13) | 32 (21) | (0.15) |
Age, years | 51 ± 7 | 63 ± 8*** | 63 ± 8*** | < 0.001 |
Current/ex-smoker, N | 12/3 | 20/9 | 19/13 | 0.36 |
Pack-years | 30 (25–40) | 50 (40–75)* | 50 (31–78)* | < 0.01 |
Systemic hypertension, N | 5 | 18 | 21 | 0.10 |
Heart failure, N | 0 | 4 | 3 | 0.32 |
Cerebrovascular event, N | 1 | 2 | 4 | 0.70 |
ICS, N | NA | 18 | 25 | 0.26 |
LABA, N | NA | 28 | 29 | 0.61 |
LAMA, N | NA | 27 | 29 | 0.99 |
Oral theophylline, N | NA | 5 | 11 | 0.15 |
White blood cell count, G/L | 9.4 ± 3.8 | 8.6 ± 2.9 | 11.1 ± 3.9# | 0.02 |
CRP, mg/L | 4 (2–6) | 5 (2–10) | 8 (3–14) | 0.05 |
FEV1, % predicted | 101 ± 14 | 47 ± 14*** | 39 ± 13*** | < 0.001 |
FVC, % predicted | 109 ± 13 | 78 ± 19*** | 65 ± 18***## | < 0.001 |
FEV1/FVC | 0.78 ± 0.08 | 0.49 ± 0.09*** | 0.47 ± 0.09*** | < 0.001 |
RV/TLC | 0.31 ± 0.05 | 0.56 ± 0.12*** | 0.58 ± 0.10*** | < 0.001 |
Raw, kPa∙s∙L−1 | 0.24 ± 0.08 | 0.46 ± 0.15*** | 0.46 ± 0.12*** | < 0.001 |
pH | NA | 7.40 ± 0.03 | 7.41 ± 0.03 | 0.49 |
pO2, mmHg | NA | 60 ± 8 | 62 ± 10 | 0.29 |
pCO2, mmHg | NA | 43 ± 8 | 42 ± 7 | 0.61 |
CAT score | NA | 19 ± 7 | 21 ± 8 | 0.16 |
FENO, ppb | 12 ± 2 | 14 ± 2 | 26 ± 3**# | < 0.01 |